#Next-Generation Sequencing

[gauricmi]

Maximizing Efficiency: Best Practices for Using Sequencing Consumables

By implementing these best practices, researchers can streamline sequencing workflows, increase throughput, and achieve more consistent and reproducible results in genetic research. Sequencing Consumables play a crucial role in genetic research, facilitating the preparation, sequencing, and analysis of DNA samples. To achieve optimal results and maximize efficiency in sequencing workflows, it's essential to implement best practices for using these consumables effectively.

Proper planning and organization are essential for maximizing efficiency when using Sequencing Consumables. Before starting a sequencing experiment, take the time to carefully plan out the workflow, including sample preparation, library construction, sequencing runs, and data analysis. Ensure that all necessary consumables, reagents, and equipment are readily available and properly labeled to minimize disruptions and delays during the experiment.

Optimizing sample preparation workflows is critical for maximizing efficiency in sequencing experiments. When working with Sequencing Consumables for sample preparation, follow manufacturer protocols and recommendations closely to ensure consistent and reproducible results. Use high-quality consumables and reagents, and perform regular quality control checks to monitor the performance of the workflow and identify any potential issues early on.

Utilizing automation technologies can significantly increase efficiency when working with Sequencing Consumables. Automated sample preparation systems and liquid handling robots can streamline repetitive tasks, reduce human error, and increase throughput. By automating sample processing and library construction workflows, researchers can save time and resources while improving consistency and reproducibility in sequencing experiments.

Get More Insights On This Topic:  Sequencing Consumables

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry.��With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[techtoio]

Biotech Breakthroughs: Cutting-Edge Innovations That Will Change Health Care

Introduction

The field of biotechnology is at the forefront of some of the most groundbreaking advancements in healthcare. With new discoveries and innovations emerging at an unprecedented rate, biotech is poised to transform the way we approach health care. From revolutionary treatments to personalized medicine, the potential of biotech to improve lives is immense. In this article, we’ll delve into the most significant biotech breakthroughs and how they are set to change health care as we know it. Read to continue

[simplyforensic]

Sequencing: A Deep Dive into the History of DNA Techniques

Sequencing: A Deep Dive into the History of DNA Techniques The evolution of DNA sequencing technologies marks a fascinating journey of scientific breakthroughs, from the early days of manual, labor-intensive methods to the current era of high-throughput, automated systems. This history can be divided into three main generational shifts, each characterized by significant advancements in…

[tekmaticinc]

Tekmatic: Next-Generation Sequencing | Explore the Technology

Next-generation sequencing (NGS) describes high-throughput methods that can swiftly determine the sequence of a specific nucleic acid strand, such as DNA or RNA. How we perform genomics research has altered as a result of these tools. There are numerous methods that use different operating principles under the umbrella term "next-generation sequencing."

[luck-of-the-drawings]

THIS THING IS SCUUUFFED AS HELL & ITS ALSO THE BEST THING I HAVE ANIMATED THUS FAR. IM SO IN LOVE WITH EMIZEL. JUST WISH I GAVE HIM MORE STUPID TATTOOS. NEXT TIME THO. NEXT TIME. I ALSO LOVE VEX&VIV SOOOO MUCH. charlies flavor of Deranged is my FAVORITE!!

[the-heart-of-a-monster]

THOAM ISSUE 7 PAGE 32

NEXT PAGE –> <– PREVIOUS PAGE

ISSUE 1 - ISSUE 2 - ISSUE 3 - ISSUE 4 - ISSUE 5 - ISSUE 6

[liquidstar]

a friend who'd wait :)

[feministfandomgeek]

we need to make using chatgpt embarrassing. what do you mean you don't care if what you write is full of nonsense presented as facts

[netherdevil]

unnormal vivilly dweller thoughts in my head

[cbirt]

Next Generation Sequencing (NGS) Data Analysis Online Training

🚀 Unlock the power of Next Generation Sequencing (NGS) and elevate your bioinformatics skills with our upcoming training course! ⭐ Why join us? In today’s rapidly evolving world of life sciences, mastering NGS data analysis is essential for cutting-edge research. Our comprehensive training programs are designed to equip you with the skills needed to excel in bioinformatics, whether you’re a beginner or looking to advance your expertise. Registrations Open: ✅ Next-Generation Sequencing Data Analysis ✅ Python & Biopython for Bioinformatics 🗓 Dates NGS Data Analysis: September 17 - October 17, 2024 Python & Biopython: September 17 - October 03, 2024 ⏰ Time: 7:00 PM - 8:00 PM IST 🗓 Registration Closes: September 15, 2024 💻 Mode: Online 🎯 Ready to make a difference in your research? Don't miss out on this opportunity to enhance your bioinformatics skills and open new doors in your career. 👉 𝐒𝐞𝐜𝐮𝐫𝐞 𝐘𝐨𝐮𝐫 𝐒𝐩𝐨𝐭 𝐓𝐨𝐝𝐚𝐲: https://lnkd.in/grUEakiP For more details/queries, contact: info@cbirt.net Feel free to reach out with any questions! #Bioinformatics#NGSDataAnalysis#Python hashtag#Biopython #TrainingCourses#CareerGrowth#BioinformaticsEducation#Students #OnlineCourses #BioinformaticsTools #ComputationalBiology #ScienceInnovation

[splicejunction]

If you see me on Spotify listening to rush limelight 45 times in a row don’t worry about it

[sshbpodcast]

Wake me up before you boldly go go: Dreams in Star Trek

By Ames

I’m feeling pretty tired at the moment, specifically tired of dream sequences in various media. They’re a fairly overused trope: seeing some slightly off scenes that either teach our protagonists something they need to know or just toy with the audience to make them believe something is real. Until the characters wake up. Even Star Trek, a show allegedly bounded by science, falls victim to the lazy writing and overused device of the dream episode.

That’s not to say there aren’t some good dream episodes out there, and even in here. So this week A Star to Steer Her By is analyzing some dreams, some nightmares, anything that we might find in the subconscious and wonder if it means anything (even if it’s just to the plot). So get tucked in, snuggle up with Kukalaka, and drift out of consciousness below and/or on this week’s podcast episode (discussion starts at 1:15:29). Let’s see if all of this was just a dream.

Somehow, we couldn’t think of any episodes from The Original Series or The Animated Series that had dream sequences, which is a little funny since you’d think the campier and arguably less cerebral shows would have some true nightmares. But we’re starting off with a whole slew of episodes from The Next Generation instead.

[images © CBS/Paramount]

“Shades of Grey”

Coma dreams are their own subsection of dream episodes, but definitely worth including in our list because they present some interesting examples of storytelling and structure. And then there’s “Shades of Grey.” As far as clipshows go, it’s got an okay wrapper in the form of some Riker dream manipulation, but it has too much going against it to be any good overall.

“Night Terrors”

Mention episodes that aren’t any good and “Night Terrors” will arise from your subconscious. As far as dream plots go, it’s actually got a decent concept in depriving everyone but Troi of REM sleep, so there are some really surreal (if disjointed) scenes, but watching what they put Marina Sirtis through proved to be the real nightmare.

“Violations”

This one’s probably in that grey area between visions and coma dreams, but worth mentioning just to bring up what a messed up thing that bastard Jev does to people – putting skewed, traumatic memories in their heads that leaves them in comas. Like in “Night Terrors,” it’s got some really upsetting scenework and direction that leaves you feeling appropriately disturbed.

“The Inner Light”

One of the best episodes of all of Star Trek is effectively a coma dream that Picard has in which he lives the life of Kamin in the twenty or so minutes that he’s knocked out by the Kataan probe. Talk about great use of the dream structure! We don’t need to deal with surreal nonsense because of the programming, and the effects on Jean-Luc are personal and emotional.

“Tapestry” 

This one is debatable based on your interpretation. On the podcast, Jake likes to spread the possibility that none of this episode happened at all and it was all a dream Picard had while on Dr. Crusher’s surgical table. Which is an interesting way to think about this genuinely thought-provoking episode, although we enjoy the other view that Q’s behind it all as well.

“Birthright”

After a certain visiting doctor zaps him in the face, Data is able to unlock his dreaming program that daddy Soong had left for him as a little present. And it’s all pretty on-the-nose kinda stuff that dream episodes can be guilty of. Every little action is meaningful in some way that is just utterly unrealistic, but Data’s also an android, so realism may already be out of the question.

“Frame of Mind”

I’d say “Frame of Mind” might be our first real example of a good traditional dream episode. It’s not just a story told in a dream or a technique for the writers to convey something without stating it. This Riker mind adventure is meant to be a disorienting experience specifically because it’s all in his head. There was method to this madness and it paid off in spades!

“Phantasms”

This infamous episode is the reason why I wanted to do this post. “Phantasms” commits pretty much every sin a dream sequence can commit: it mainly uses characters from the episode in absurd roles, the dream makes too much sense in world because everything in it correlates to something from real life, and its randomness and surrealness just come across as a formulaic writing device. With mint frosting.

“Dark Page”

Literally on the heels of “Phantasms” is what I’d call a more interesting and effective use of the dream, in this case the coma dream that Deanna visits inside Lwaxana’s head. The symbolism isn’t as overt and at the same time there’s more emotional connection with the scenelettes. I also give it a pass because Betazoid mind powers help this one from feeling too heavy handed.

First Contact

Somehow, we don’t see a guilt-driven dream sequence in Star Trek until First Contact, and it’s just a pretty typical but effective little scene to inform the audience of Picard’s mindset and a little bit of backstory that you might need to understand the movie. Is it the most original way to convey this information? No, but it’s not a terrible offense either and it does its job well.

“Distant Voices”

One of our least favorite episodes of all of Deep Space Nine was all just a ridiculous coma dream in Bashir’s head. If this one isn’t the worst dream episode of Trek, I don’t know what is. Like “Phantasms,” it’s got every element of the dream symbolizing something and some very tiring tropey motifs. And I haven’t even gotten to the confounding acting decisions!

“Hard Time”

While Picard got to experience a life’s worth of touching memories in “The Inner Light,” O’Brien gets to experience a life’s worth of suffering in “Hard Time.” It may have only been a couple of hours in real time, but the dream that he sustains has huge impacts on his character and makes for a really thought-provoking and riveting episode.

“Body Parts”

When he’s destined to die to relinquish his desiccated remains to Brunt, Quark at one point has one of those trauma dreams that is a writer’s shorthand for “this is what my character is preoccupied with!” In this case, he dreams of the first Nagus Gint advising him to break the contract because someone needed to propel the plot forward, I guess.

“Business as Usual” 

If “Body Parts” was a little obvious, then the dream in “Business as Usual” is downright heavy handed. Quark is feeling guilty about selling weapons on the black market, and if you weren’t sure he had a conscience, this dream sequence underlines it for you. Normally, I’d poopoo a scene like this, but O’Brien yelling “You killed my baby!” really sells it.

“Far Beyond the Stars” 

Coma dream or prophet vision? I don’t feel like arguing for the Benny Russell  story coming from some supernatural meddling versus from Sisko’s dreams, and it’s such a good episode that it’s worth bringing up anyway. And if we’re counting external meddling like in “The Inner Light” and “Hard Time,” then who am I not to include another really great episode that’s all in your head?

“Extreme Measures”

Similarly, I guess if I include “Dark Page” and “Distant Voices,” then I have to include “Extreme Measures,” though in a perfect world, I wouldn’t give it the satisfaction because it’s a really upsetting and invasive episode that turns Bashir into some kind of brain-robbing monster. And frankly, the inside of Sloan’s mind didn’t even end up being all that interesting!

“Jetrel”

Update 1/28/24: Oh no, we forgot one (or two, or probably more because dammit)! And it’s yet another of our favorite “this character is feeling conflicted about X” plot devices because writers think the audience is incapable of picking up on subtext! This time, Neelix’s history is dredged back up when Jetrel, the creator of the Metreon Cascade” pops by, and for some reason we need to see that Neelix is still having survivor’s guilt through traumatic dream vision.

“The Thaw”

Lotta coma dreams on this list so far, and our first taste from Voyager is the stuff of nightmares, literally. Fear the Clown takes what should be a paradisiacal shared dream for our friends in their cryopods and turns it into a horror movie and you could wake up dead. This one gets points for creativity, and points off for giving us all coulrophobia.

“Remember”

We really liked this one when we covered it in season three, even if it’s some more familiar ground. Reliving another culture through implanted dreams? Sure, it’s yet another instance where we can make parallels to something like “The Inner Light,” but it’s forgivable since this episode is so successful at communicating the Enarans’ story in Torres’s dreams.

“Coda”

I’d probably qualify whatever is going on with Janeway throughout this episode as something like the coma dreams we’ve discussed previously. It’s all alien interference, as happens sometimes, and winds up being like one of those episodes that pulls back the curtain and tricks you because it was fake all along, leaving the viewer ultimately unsatisfied.

“Waking Moments”

More alien intervention, this time into a world where the new species lives and communicates through dreams. Suspend your disbelief for a moment and accept that, difficult as it may be, and we actually do get some pretty original and believable dream sequences. The ones we see don’t try to go too far and mainly seem kinda right for the characters, so this one passes.

“The Fight”

But this one just fails utterly. We discussed in our recent season wrap episode how “The Fight” just seems like a chaotic mess and yet at the same time doesn’t capitalize on the Chaotic Space aliens in a way that is fulfilling. So we’re left with dream sequences that end up just feeling tired and confusing and maybe a little bit boring. Someone bet on the wrong fighter in this ring.

“One” 

While most of what Seven experiences in “One” is all delusion and hallucination, she does have a legitimate dream of being in an Arctic wasteland at one point. And sure, it’s there to convey that she’s feeling alone and desolate and way out of her depth like a pretty standard dream metaphor, but the little sequence does its job. The CGI on the other hand…

“Barge of the Dead”

Like with “Coda,” I’d qualify all of this episode as a coma dream, though instead of being induced by aliens, we’re led to believe that all of this is just some Klingon afterlife nonsense. Setting aside that everyone assumes Gre’thor is real now, the dreams we get of Torres’s personal hell – just people on the Voyager? – are half baked and entirely out of character.

“Tinker, Tenor, Doctor, Spy”

These are more daydreams than subconscious dreams, though the EMH’s program does get out of hand enough that I’d count this episode among the others in this post. The scenes we get are mostly meant to be comic relief so we can giggle at the EMH’s grandiose fantasies, except that some of them are fairly cringey, as usual at Seven’s expense.

“Memorial”

Memory or dream? That’s the question this episode poses in creating an actually pretty intriguing look at how and why we remember history. The dream sequences we get from Paris and Chakotay are very effective at blurring that line between the real and the surreal, and the more we understand that these were real events, the more we treat them with significance.

“Ashes to Ashes”

Update 1/28/24: Whoops, another I’d forgotten until we continued our Voyager watchthrough. It’s a small one, but Lyndsay Ballard’s dream sequence when she returns from the dead and back to the Voyager crew fit the old “show the audience the character is feeling conflicted” trope. She guilt-dreams that her friends are throwing her another funeral because she’s not acclimating back to life as a human. The scene does what it’s made to; it’s just entirely redundant.

“Shuttlepod One”

Let’s move on to Enterprise, starting with a pretty mean trick that dream sequences can do to an audience: manipulating you for a couple minutes into thinking that our heroes have been rescued and everything’s okay, until the rug gets pulled out from under you and it was all just a dream. The scene also leans on another trend we’ll see in Enterprise – objectifying T’Pol all the damn time.

“Fusion”

But the winner of the “objectifying T’Pol all the damn time” award is very obviously “Fusion.” Boy, what an upsetting episode. If you thought it was gross what Jev did to Troi and the others in “Violations,” then “Fusion” should have you gagging, and it all starts with a super gross dream sequence in which Tolaris creeps on T’Pol, and things get ickier from there.

“A Night in Sickbay”

Update 1/28/24: How could we forget yet another time that one of the characters had a wetdream about T’Pol? This time, it’s Archer because Phlox has put it in the cap’n’s head that he’s actually in love with the subcommander like a creep. The nightmare sequence also features another guilt-ridden message (a dream staple!) in which Archer is feeling so bad Porthos is sick that he dreams up a puppy funeral. Ugh.

“Vanishing Point”

Just when you think you’ve watched an interesting transporter accident episode that actually gives Hoshi something to do, this episode laughs in your face and pulls the “it was a dream the whole time” trick on you. The whole thing comes across as just kind of cruel and cop-out-y, though I’m kinda shocked there aren’t many other Trek episodes that consciously pull this stunt.

“Remembrance” 

Say what you will about Picard season one (and we did!), but the dream sequences of Jean-Luc obsessing over the loss of Data are very effective at eliciting an emotional response. They’re just strange enough to provide that surreal quality of dreams but not just tedious nonsense like other episodes have given us. And the scenes are just so touching that it’s hard to fault them.

“The Impossible Box”

Okay, last one I could find. Soji has these recurring trauma-fueled dreams and she can’t tell if it’s a dream or a memory. This whole episode is an identity crisis waiting to happen, and when she sees herself as a wooden puppet being constructed, it all comes together that she isn’t a real girl, and you know what, it’s both one of the better uses of dreams and one of the better moments in Picard!

—

Wake up! You’re going to be late for school and you didn’t study for that test and you’re naked and your teeth are falling out and Troi’s a cake and won’t somebody answer the phone?! 

Put a pot of coffee on and stay with us for more dreamy blogposts. You can also share that caffeinated brew with our fearless Voyager captain as we continue through our full watchthrough on SoundCloud or wherever you listen to podcasts, respond to our wake up call on Facebook and Twitter, and have pleasant dreams!

[simplyforensic]

The Dawn of Next Generation Sequencing Technologies: A Revolution in Genomic Science

In genomic science, the advent of Next-Generation Sequencing (NGS) technologies has marked a transformative era, radically changing our approach to understanding the complexities of life at a molecular level. NGS, also known as high-throughput sequencing, encompasses several advanced methodologies that enable rapid sequencing of DNA and RNA much more swiftly and cost-effectively than…

[tekmaticinc]

Next-Generation Sequencing | Explore the Technology - Tekmatic 

The term "next-generation sequencing" (NGS) refers to high-throughput technologies that can quickly ascertain the sequence of a particular nucleic acid strand, such as DNA or RNA. These tools have changed how we conduct genomics research. "Next-generation sequencing" refers to various technologies that operate according to various operating principles.

[businessmarketreports]

An Overview of Next Generation Sequencers Market: Trends and Insights

The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.

Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report

This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.

1. Market Overview

Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.

Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.

Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.

2. Key Trends in the NGS Market

Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.

Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.

Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.

Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.

Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.

Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.

3. Market Segmentation

By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.

By Technology:

Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.

Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.

RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.

Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.

By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.

By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.

4. Key Drivers and Challenges

Drivers:

Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.

Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.

Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.

Challenges:

Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.

Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.

High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.

5. Competitive Landscape

The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.

Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.

Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.

Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.

Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.

BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.

Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.

Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.

6. Future Outlook

Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.

Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.

Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.

Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.

Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.

Conclusion

The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.